Japanese Encephalitis Virus Inactivated Vaccine
Last Updated: May 22, 2013
Products Affected - Description
JE-VAX® lyophilized vaccine for injection, Sanofi Pasteur
Single-dose vial (NDC 49281-0680-30) – discontinued
Reason for the Shortage
The manufacturer of JE-VAX® discontinued production of the vaccine in 2006. All remaining inventory was exhausted in 2011.1,2
Estimated Resupply Dates
- JE-VAX® was discontinued in February 2011.1
- Novartis has available Ixiaro® (NDC 42515-0001-01), a cell-culture derived vaccine for prevention of Japanese Encephalitis. Ixiaro® is labeled for use in patients 2 months of age and older.3
Implications for Patient Care
- Ixiaro® is labeled for use in patients 2 months of age and older.4
- Ixiaro® requires 2 doses to complete a series. 3
- Ixiaro® is administered as an intramuscular injection. This route differs from JE-VAX®, which was administered subcutaneously.3,4
- Haemophilus B Conjugate Vaccine — Current
- Meningococcal Vaccines — Current
- Poliovirus Vaccine Inactivated — Current
- Sanofi Pasteur (written communication). February 23, 2011.
- Fischer M, Lindsey N, Staples JE, Hills S; Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 Mar 12;59(RR-1):1-27.
- Ixiaro (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) suspension for intramuscular injection [product information]. Novartis Vaccines and Diagnostics. Cambridge, MA; May 2013
- JE-VAX (Japanese Encephalitis Virus Vaccine, Inactivated) [product information]. Sanofi Pasteur. Swiftwater, PA; December 2005.
May 22, 2013; February 25, 2011, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.